These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33759400)
1. A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Zheng Y; Stafford PM; Stover KR; Mohan DC; Gupta M; Keske EC; Schiavini P; Villar L; Wu F; Kreft A; Thomas K; Raaphorst E; Pasangulapati JP; Alla SR; Sharma S; Mittapalli RR; Sagamanova I; Johnson SL; Reed MA; Weaver DF ChemMedChem; 2021 Jul; 16(14):2195-2205. PubMed ID: 33759400 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Kong KM; Zhang JW; Liu BZ; Meng GR; Zhang Q Bioorg Med Chem Lett; 2020 Feb; 30(4):126901. PubMed ID: 31882299 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors. Cui G; Lai F; Wang X; Chen X; Xu B Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488 [TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. Tomek P; Palmer BD; Flanagan JU; Sun C; Raven EL; Ching LM Eur J Med Chem; 2017 Jan; 126():983-996. PubMed ID: 28011425 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors. Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925 [TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening. Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246 [TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors. Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors. Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191 [TBL] [Abstract][Full Text] [Related]
9. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy. Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059 [TBL] [Abstract][Full Text] [Related]
10. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy. Weng T; Qiu X; Wang J; Li Z; Bian J Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788 [TBL] [Abstract][Full Text] [Related]
11. A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Xu H; Song Y; Yang Q Chem Pharm Bull (Tokyo); 2017; 65(8):714-717. PubMed ID: 28768924 [TBL] [Abstract][Full Text] [Related]
12. Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. Xu X; Ren J; Ma Y; Liu H; Rong Q; Feng Y; Wang Y; Cheng Y; Ge R; Li Z; Bian J J Enzyme Inhib Med Chem; 2019 Dec; 34(1):250-263. PubMed ID: 30734612 [TBL] [Abstract][Full Text] [Related]
13. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1). Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity Relationship of Indomethacin Derivatives as IDO1 Inhibitors. Obata T; Shiratani S; Nada T; Kasaya Y; Arisawa M; Shuto S; Tanaka M Anticancer Res; 2021 May; 41(5):2287-2296. PubMed ID: 33952454 [TBL] [Abstract][Full Text] [Related]
15. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors. Gao D; Li Y Bioorg Med Chem; 2017 Jul; 25(14):3780-3791. PubMed ID: 28526475 [TBL] [Abstract][Full Text] [Related]
16. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors. Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421 [TBL] [Abstract][Full Text] [Related]
17. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO). Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341 [TBL] [Abstract][Full Text] [Related]
18. Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties. Qian S; He T; Wang W; He Y; Zhang M; Yang L; Li G; Wang Z Bioorg Med Chem; 2016 Dec; 24(23):6194-6205. PubMed ID: 27769672 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor. Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays. Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]